<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621357</url>
  </required_header>
  <id_info>
    <org_study_id>2017_70</org_study_id>
    <secondary_id>2019-A02502-55</secondary_id>
    <nct_id>NCT04621357</nct_id>
  </id_info>
  <brief_title>Influence of Cerebral Oedema in Intracerebral Haemorrhage</brief_title>
  <acronym>COPITCH</acronym>
  <official_title>Consequences of Oedema on the Prognosis of InTraCerebral Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conseil RÃ©gional Hauts-de-France, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation pour la recherche sur les AVC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides&#xD;
      stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema&#xD;
      (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history&#xD;
      as well as the clinical impact of this PHO remain unclear. The COPITCH study has been&#xD;
      designed to answer these questions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Poor functional outcome defined as a modified Rankin Scale of 4 or more</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall distribution of the modified Rankin scale at 3- and 12 months</measure>
    <time_frame>at 3 months and 12 months</time_frame>
    <description>The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.&#xD;
The scale runs from 0-6, running from perfect health without symptoms to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurological deterioration defined as more than 4 points on the NIHSS score</measure>
    <time_frame>at 96 hours</time_frame>
    <description>The NIHSS score (NIH Stroke Scale) is used to monitor the progression of an ischemic or hemorrhagic stroke. It is rated from 0 to 42 points. Depending on the result, a distinction is made from Minor stroke to Severe stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality at 3 and 12 months</measure>
    <time_frame>at 3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive decline</measure>
    <time_frame>at 3 months, at 12 months</time_frame>
    <description>Cognitive decline defined as a score on MOCA test below 27</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Stroke</condition>
  <condition>Intra Cerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Patient with intracerebral haemorrhage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>Brain MRI will include differents sequences.</description>
    <arm_group_label>Patient with intracerebral haemorrhage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological biomarkers</intervention_name>
    <description>Biological biomarkers will include a set of systemic inflammatory markers</description>
    <arm_group_label>Patient with intracerebral haemorrhage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With a spontaneous ICH, i.e. non traumatic&#xD;
&#xD;
          -  Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well&#xD;
             will be considered as stroke onset&#xD;
&#xD;
          -  Patient insured under the French social security&#xD;
&#xD;
          -  Consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pure intraventricular haemorrhages&#xD;
&#xD;
          -  &quot;secondary&quot; ICH: ICH resulting from intracranial vascular malformation, intracranial&#xD;
             venous thrombosis, head trauma or tumour; haemorrhagic transformation within an&#xD;
             infarct&#xD;
&#xD;
          -  Pre-admission modified Rankin score of 4 or 5&#xD;
&#xD;
          -  Life expectancy of less than 1 year related to comorbidities (end stage cancer, end&#xD;
             stage organ failure)&#xD;
&#xD;
          -  Pregnancy or breastfeeding or Women of childbearing age without effective&#xD;
             contraception (a pregnancy test will be done)&#xD;
&#xD;
          -  Adults who are deprived of their liberty by judicial or administrative decision&#xD;
&#xD;
          -  Referral from other hospitals&#xD;
&#xD;
          -  Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental&#xD;
             or other) or in a risk area (nervous or vascular system);irremovable implanted medical&#xD;
             device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve&#xD;
             (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms;&#xD;
             gadolinium allergy&#xD;
&#xD;
          -  No consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Cordonnier, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Cordonnier, MD,PhD</last_name>
    <phone>0320445962</phone>
    <email>charlotte.cordonnier@chru-lille.fr</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intra Cerebral Hemorrhage</keyword>
  <keyword>Perihaematomal oedema</keyword>
  <keyword>MRI</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

